On 21st April 2010, SOLYSTIC celebrated the installation of their 1,000 th MARS machine in the Mail Processing Facility at Thonon-les-Bains (France). The MARS carrier route sequencing machine, designed for individual postal rounds, has become the worldwide standard in its category, due to its remarkable performance levels – 12,000 mail items per hour, sorted in a three pass mode and more than 41,000 mail pieces an hour in classic mode, not forgetting its reliability and simplicity of use.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/solystic/42413/
On 21st April 2010, SOLYSTIC celebrated the installation of their 1,000 th MARS machine in the Mail Processing Facility at Thonon-les-Bains (France). The MARS carrier route sequencing machine, designed for individual postal rounds, has become the worldwide standard in its category, due to its remarkable performance levels – 12,000 mail items per hour, sorted in a three pass mode and more than 41,000 mail pieces an hour in classic mode, not forgetting its reliability and simplicity of use.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/solystic/42413/
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
Advanced technology has the power to transform healthcare, a world leader in the field of genomicsDr Leroy Hood, has said ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430051-dr-leroy-hood-astellas-debate/
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
BloodCenter of Wisconsin’s Diagnostic Laboratories today announced the availability of a comprehensive cancer mutation HemeOnc Panel using next generation sequencing (NGS) technology. The NGS panel developed by BloodCenter of Wisconsin is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7363151-bloodcenter-of-wisconsin-launches-next-generation-sequencing-hemeonc-panel/
Strand Life Sciences (Strand) announced today the version 2.0 release of its popular next-generation sequencing (NGS) data analysis and visualization platform, Avadis NGS, under a new name: Strand NGS. Strand NGS is built on the same award winning platform as Strand and Agilent Technologies’ GeneSpring®.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400564-Avadis-NGS-becomes-Strand-NGS
